Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
uniQure BV (QURE) PT Raised to $175 at Chardan Capital Markets
-
Chardan Capital Markets Downgrades Solid Biosciences (SLDB) to Neutral
-
Form 10-Q Chardan Healthcare Acqui For: Mar 31
-
Chardan Serves as Lead Left Joint Book-Running Manager for Health Sciences Acquisitions Corporation
-
Health Sciences Acquisitions Corporation (HSACU) Prices 10M Unit IPO at $10/Unit
-
Health Sciences Acquisitions Corporation Announces Pricing of $100 Million Initial Public Offering
-
Arbutus Biopharma (ABUS) PT Lowered to $5 at Chardan Capital Markets
-
eHealth (EHTH) PT Raised to $87 at Chardan Capital Markets
-
Chardan Capital Markets Starts Kaleido Biosciences Inc. (KLDO) at Buy
-
PlacementTracker Publishes Q1 2019 PIPE and Private Placement Markets League Tables
-
DMC Global (BOOM) PT Increases To $79 At Chardan
-
8i Enterprises Acquisition Corp. Announces Underwriters' Full Exercise of Over-Allotment Option in Connection with Its Initial Public Offering
-
Histogenics (HSGX) to be Acquired by Ocugen
-
Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics
-
Chardan Capital Markets Starts Smith Micro Software (SMSI) at Buy
-
Chardan Capital Markets Starts Moderna (MRNA) at Buy
-
Editas Medicine (EDIT) Buy Reiterated At Chardan After Strategic Collaboration Announcement
-
8i Enterprises Acquisition Corp. Announces Closing of Initial Public Offering
-
8i Enterprises Acquisition Corp. (JFK) Prices 5M Unit IPO at $10/Unit
-
8i Enterprises Acquisition Corp. Announces Pricing of $50 Million Initial Public Offering
-
Chardan Capital Markets Starts Exicure (XCUR) at Buy
-
Arcimoto, Inc. (FUV) Reports 800K Share Registered Direct Offering at $4.25/Sh
-
Arcimoto Announces $3.4 Million Common Stock Only Registered Direct Offering
-
Chardan Capital Markets Reiterates Buy Rating on Arcimoto Inc. (FUV) on New Delivery Vehicle
-
Foresight Autonomous Holdings Ltd. Closes Offering of 4,100,000 American Depositary Shares Including Partial Exercise of Over-Allotment Option
-
Adverum Biotechnologies to Participate in Upcoming Conferences
-
Foresight Autonomous (FRSX) Prices 4M Offering at $1.50/ADS
-
Foresight Autonomous Holdings Ltd. Prices Offering of 4,000,000 American Depositary Shares
-
Caladrius Biosciences (CLBS) PT Lowered to $6 at Chardan Capital Markets
-
Foresight Autonomous (FRSX) Announces Proposed ADS Offering
-
Foresight Autonomous Holdings Ltd. Announces Proposed Public Offering of American Depositary Shares
-
Vuzix Corp. (VUZI) Verizon Reseller Agreement Should Bring Meaningful Revenue - Chardan
-
ADMA Biologics (ADMA) Results Still Waiting For CRL To Be Lifted - Chardan
-
Chardan Healthcare Acquisition Corp. Securities To Commence Separate Trading
-
Krystal Biotech (KRYS) PT Raised to $57.50 at Chardan Capital Markets
-
Chardan Capital Markets Downgrades Profire Energy (PFIE) to Neutral
-
Spring Bank Pharmaceuticals (SBPH) PT Lowered to $25 at Chardan Capital Markets
-
Chardan Capital Markets Upgrades Axovant Gene Therapies Ltd. (AXGT) to Buy
-
22nd Century Group (XXII) Key Resignation Puts Pipeline In Question - Chardan
-
Seres Therapeutics to Present at Three Upcoming March Conferences
-
uniQure BV (QURE) PT Raised to $100 at Chardan Capital Markets
-
UPDATE: Chardan Capital Markets Starts Invitae Corporation (NVTA) at Buy
-
Form X-17A-5 CHARDAN CAPITAL MARKETS For: Dec 31
-
Synlogic to Present at Investor Conferences in March
-
Chardan Capital Markets Starts Infant Bacterial Therapeutics AB (IBTB:SS) at Buy
-
Tocagen Inc. (TOCA) PT Lowered to $25 at Chardan Capital Markets
-
Chardan Capital Markets Downgrades ORBCOMM (ORBC) to Neutral
-
MeiraGTx Holdings plc (MGTX) PT Raised to $40 at Chardan Capital Markets; 3rd Investment by J&J
-
NanoViricides (NNVC) Announces $2.5 Million Financing in Registered Direct Offering of Common Stock, Warrants
-
NanoViricides Announces $2.5 Million Financing in a Registered Direct Offering

